Compare LADR & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LADR | AVLN |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2013 | 2026 |
| Metric | LADR | AVLN |
|---|---|---|
| Price | $9.85 | $28.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $12.25 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 520.1K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 8.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.66 | N/A |
| Revenue Next Year | $16.92 | N/A |
| P/E Ratio | $485.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.61 | $27.33 |
| 52 Week High | $11.92 | $33.32 |
| Indicator | LADR | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 32.04 |
| Support Level | $9.61 | $27.37 |
| Resistance Level | $10.44 | $29.48 |
| Average True Range (ATR) | 0.18 | 2.48 |
| MACD | -0.04 | -0.30 |
| Stochastic Oscillator | 25.53 | 14.40 |
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments: Loans, which derive maximum revenue; Securities; and Real Estate.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.